NGeneBio registered a Korean patent for the analysis algorithm of cancer-related genetic variants. The patent name is “CNV detection technique and analysis device based on lead depth.”
NGeneBio applies this technology to its precision diagnostic analysis platform, NGeneAnalySys, and uses it to diagnose breast cancer and ovarian cancer. The scope of diagnosis was expanded by accurately deriving not only the simple point mutation but also the copy-number variation.
For the full Korean press release, head over to the below link.
June 30, 2021 @South Korea